A 21st century epidemic: As incidence rates of type 2 diabetes mellitus (T2DM) continues to rise, there is a growing need to identify novel therapeutics with improved efficacy and reduced side effects. Here, the medicinal chemistry of approved incretin mimetics and DPP-4 inhibitors is described along with the pharmacological background and late-stage clinical developments currently in the pipeline.
No takes yet. Share an insight, caveat, or question.
Zettl et al. (2009) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: